Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 836858 in Low/Int-1 Risk MDS
NCT02240706Phase 2Terminated
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2015
- Primary completion
- Nov 2019
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of BI 836858 in myelodysplastic syndrome (MDS), sponsored by Boehringer Ingelheim. Started Jan 2015; status: terminated.
02
Drugs
BI 836858
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02240706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02240706.